Cognitive Impairment Related to Atrial Fibrillation Prevention Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT01994265
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 200 participants
- Registry
-
NCT01994265
-
- Other papers using this trial's data
- Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT01994265. Randomized; single masking; primary purpose prevention. Start 2014-11-07 (registry gives no type); primary completion 2021-03-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cognitive Impairment Related to Atrial Fibrillation Prevention Trial
- Acronym
- GIRAF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Warfarin
- Intervention (Drug)
- Dabigatran
- Lead sponsor
- University of Sao Paulo
- Collaborator
- Federal University of Minas Gerais
- Collaborator
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct01994265- Content hash
8e3fa6c545f29834200e0d07caba238224b45fc4b8b0d67cf1e2c9bf85e33102